TITLE:
Co-administration Study in Patients With Elevated Cholesterol and Coronary Heart Disease (0653-803)

CONDITION:
Hypercholesterolemia

INTERVENTION:
MK0653, ezetimibe

SUMMARY:

      The purpose of this study is to investigate additional cholesterol lowering effects in
      patients with coronary heart disease by giving an investigational drug with a patient's
      current approved cholesterol lowering medication.
    

DETAILED DESCRIPTION:

      The duration of treatment is 10 weeks.
    

ELIGIBILITY:
Gender: All
Age: 18 Years to N/A
Criteria:

        Inclusion Criteria:

          -  Patients with elevated cholesterol and coronary heart disease

        Exclusion Criteria:

          -  Patients who have cholesterol levels within normal ranges as identified by the study
      
